Section
Pipeline
Late-stage drugs with significant commercial implications
PipelineFiercePharma ↗
After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone syntha…
PipelineFiercePharma ↗
Already tracking $5 billion in annual sales, Enhertu has secured two new FDA approvals for treating early brea…
PipelinePharmaVoice ↗
As next-generation GLP-1 contenders rise, key readouts are on the way from Pfizer, Viking Therapeutics and Eli…
PipelineEndpoints News ↗
Regeneron Pharmaceuticals’ LAG-3 inhibitor called fianlimab has flunked a late-stage skin cancer trial, markin…
PipelineFierceBiotech ↗
Aardvark Therapeutics is planning to unblind data from its phase 3 Prader-Willi syndrome program after the FDA…
PipelineBriefing
Regenxbio met the efficacy bar in its pivotal Duchenne muscular dystrophy trial and is planning for FDA approv…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.